We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+25.89%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$123M
AUM Growth
+$4.73M
Cap. Flow
-$17.5M
Cap. Flow %
-14.2%
Top 10 Hldgs %
61.58%
Holding
49
New
16
Increased
11
Reduced
12
Closed
8

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$2.84M
2
CMPS
Compass Pathways
CMPS
+$2.73M
3
INSM icon
Insmed
INSM
+$2.61M
4
MREO
Mereo BioPharma
MREO
+$2.41M
5
PCVX icon
Vaxcyte
PCVX
+$2.25M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$13M
2
DYN icon
Dyne Therapeutics
DYN
+$6.62M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$5.78M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$4.34M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$3.39M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRVI icon
26
Trevi Therapeutics
TRVI
$2.63B
$970K 0.79%
290,500
+30,500
+12% +$90.7K
UNCY icon
27
Unicycive Therapeutics
UNCY
$138M
$807K 0.65%
+197,920
New +$795K
LQDA icon
28
Liquidia Corp
LQDA
$7.95B
$735K 0.6%
+73,500
New +$803K
VERV
29
DELISTED
Verve Therapeutics
VERV
$707K 0.57%
+146,100
New +$849K
GERN icon
30
Geron
GERN
$1.01B
$703K 0.57%
+154,900
New +$704K
CELC icon
31
Celcuity
CELC
$4.55B
$695K 0.56%
46,600
+1,600
+4% +$26.4K
ARTV
32
Artiva Biotherapeutics
ARTV
$566M
$680K 0.55%
+44,000
New +$510K
TECX
33
Tectonic Therapeutic
TECX
$570M
$415K 0.34%
+13,700
New +$250K
CRBP icon
34
Corbus Pharmaceuticals
CRBP
$180M
$382K 0.31%
18,500
-46,000
-71% -$2.35M
RAPP
35
Rapport Therapeutics
RAPP
$2.22B
$360K 0.29%
17,600
-2,400
-12% -$51.6K
CYPH
36
Cypherpunk Technologies Inc
CYPH
$71.7M
$310K 0.25%
120,500
-74,500
-38% -$183K
CLYM
37
Climb Bio
CLYM
$802M
$275K 0.22%
+54,000
New +$382K
BNTC icon
38
Benitec Biopharma
BNTC
$451M
$274K 0.22%
+29,800
New +$267K
TVTX icon
39
Travere Therapeutics
TVTX
$5.89B
$266K 0.22%
+19,000
New +$198K
THRD
40
DELISTED
Third Harmonic Bio
THRD
$210K 0.17%
+15,508
New +$192K
NUVB.WS
41
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$8.89K 0.01%
90,832
– –
AGIO icon
42
Agios Pharmaceuticals
AGIO
$1.91B
– –
-78,700
Closed -$3.39M
CLRB icon
43
Cellectar Biosciences
CLRB
$20.1M
– –
-2,350
Closed -$176K
NAMS icon
44
NewAmsterdam Pharma
NAMS
$3.23B
– –
-22,500
Closed -$432K
ORIC icon
45
Oric Pharmaceuticals
ORIC
$1.34B
– –
-96,000
Closed -$679K
PLRX icon
46
Pliant Therapeutics
PLRX
$65M
– –
-46,200
Closed -$497K
SRPT icon
47
Sarepta Therapeutics
SRPT
$1.77B
– –
-27,500
Closed -$4.34M
SVRA icon
48
PUT
Savara
SVRA
$1.19B
– –
-250
Closed -$101K
VRDN icon
49
Viridian Therapeutics
VRDN
$2.49B
– –
-199,433
Closed -$2.59M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return

Acuta Capital Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Acuta Capital Partners held 49 positions worth $123M, up 4% from $119M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Acuta Capital Partners withdrew a net $17.5M in Q3 2024, closing 8 positions and reducing 12 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $4.34M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Ascendis Pharma A/S worth $3.14M.

  • Acuta Capital Partners's largest Q3 2024 buy was Ascendis Pharma A/S: 21,000 shares worth $3.14M.
  • Acuta Capital Partners added most to Insmed in Q3 2024, an estimated $2.61M increase.
  • Acuta Capital Partners's biggest Q3 2024 reduction was Ocular Therapeutix, cutting an estimated $13M.
  • Acuta Capital Partners fully exited Sarepta Therapeutics in Q3 2024, selling an estimated $4.34M.
  • Acuta Capital Partners's ten largest holdings make up 62% of its $123M portfolio in Q3 2024.
  • Acuta Capital Partners opened 16 new positions and closed 8 in Q3 2024.
  • Acuta Capital Partners's portfolio value rose 4% quarter-over-quarter to $123M.

Based on Acuta Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.